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summARy – Therapeutic plasma exchange (Tpe) is a well-established therapeutic procedure 
commonly used in many neurologic immune-mediated disorders. it is thought that the beneficial 
effects of Tpe occur through elimination of pathognomonic autoantibodies, immune complexes, 
inflammatory mediators, complement components and cytokines, which play a crucial role in many 
kinds of neurologic autoimmune disease. in various neurologic disorders, randomized controlled 
studies have demonstrated the efficacy of Tpe (e.g., in acute inflammatory demyelinating polyneu-
ropathy (guillain-Barré syndrome), chronic inflammatory demyelinating polyradiculoneuropathy, 
myasthenia gravis and paraproteinemic polyneuropathies). For these disorders, Tpe is accepted as 
first-line therapy, either as a primary standalone treatment or in conjunction with other modes of 
treatment. Although widely used, the potential benefit of Tpe in the treatment of acute dissemina-
ted encephalomyelitis, chronic focal encephalitis (Rasmussen’s encephalitis), lambert-eaton mya-
sthenic syndrome, multiple sclerosis and neuromyelitis optica (Devic’s disease) is less clear. For these 
disorders, Tpe is accepted as second-line therapy, either as a standalone treatment or in conjunction 
with other modes of treatment.
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There have been great developments in the fields 
of medical technology and new medication, but we 
still are facing diseases that have no good treatments 
available. it is known that autoantibodies and immune 
complexes play a crucial role in many kinds of autoim-
mune disease. Removing these pathogenic substances 
from patient plasma may be an efficient means of 
treatment. When therapeutic plasma exchange (Tpe) 
became clinically available in the early 1970s, several 
spectacular treatment results in otherwise deleteri-
ous clinical situations were reported. These included 
life-threatening pulmonary hemorrhage in acute in-
flammatory demyelinating polyradiculoneuropathy 
(AiDp; goodpasture’s syndrome), myasthenic crisis, 
and thrombotic thrombocytopenic purpura (TTp)1-3. 
Data published during the last 30 years allow for a 
more critical view on the role of Tpe in the intensive 
care setting.
Therapeutic plasma exchange has become an es-
tablished therapeutic procedure in neurologic practice 
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for numerous pathologic conditions. in fact, the lat-
est review of plasma exchange use by the Canadian 
Apheresis group indicates that 3 neurologic disorders, 
myasthenia gravis (mg), guillain-Barré syndrome, 
and chronic inflammatory demyelinating polyneu-
ropathy (CiDp) are among the 5 most frequent indi-
cations for this therapy4. The neurologic indications 
belong primarily to Category i or ii, according to 
the guidelines of the American society for Aphere-
sis5 (Table 1). To define the current role of Tpe, 
Brunetta-gavranić et al. retrospectively analyzed 
changes in the indications for Tpe in our database, 
which contains information on all Tpes conducted 
during 27 years at Zagreb university hospital Cen-
ter (a national referral center for therapeutic aphere-
sis, which covers approximately 90%-95% of all Tpes 
performed in Croatia)6. The number of patients (in-
cluding children and elderly people) who underwent 
this procedure and Tpes increased several-fold over 
27 years of follow-up despite changes in the pattern of 
indications and the emergence of new, more selective 
therapeutic options (lDl-apheresis, immunoadsorp-
Table 2. Indications for therapeutic apheresis5
Category Description
i Disorders for which apheresis is accepted as first-line therapy, either as a primary standalone treatment or in conjunction with other modes of treatment.
ii Disorders for which apheresis is accepted as second-line therapy, either as a standalone treatment or in conjunction with other modes of treatment.
iii optimum role of apheresis therapy is not established. Decision making should be individualized.
iv
Disorders in which published evidence demonstrates or suggests apheresis to be ineffective or harmful. 
institutional Review Board approval is desirable if apheresis treatment is undertaken in these circum-
stances.
Table 1. Neurologic indication categories for urgent therapeutic apheresis (TA)









myasthenia gravis Tpe i 1A
paraproteinemic polyneuropathies* Tpe i 1B or 1C
Acute disseminated
encephalomyelitis Tpe ii 2C
Chronic focal encephalitis
(Rasmussen's encephalitis) Tpe ii 2C
lambert-eaton myasthenic syndrome Tpe ii 2C
multiple sclerosis** Tpe ii 1B
neuromyelitis optica (Devic's syndrome) Tpe ii 1C
 *special condition: igA/igg – recommendation grade, 1B; igm – recommendation  grade, 1C
**special condition: acute Cns inflammatory demyelinating disease unresponsive to  steroids
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tion, etc.). The disorder that most frequently resulted 
in an indication for Tpe was myasthenia gravis (mg; 
577 indications, 55% of all indications), with 2783 
procedures done over 27 years. The second most com-
mon indication for Tpe was thrombotic thrombocy-
topenic microangiopathy (TTp and hemolytic uremic 
syndrome, hus) with 91 indications and 1060 Tpe 
procedures. The third was guillain-Barré syndrome 
(84 indications, 498 procedures). The number of 
Tpes performed for desensitization before bone mar-
row transplantation and for hyperviscosity syndrome 
due to Waldenström macroglobulinemia and mul-
tiple myeloma also increased significantly in the last 
decade (41 indications, 83 Tpes and 25 indications, 
161 Tpes, respectively). A comparable increase has 
been recorded in the number of patients who needed 
Tpe for rapidly progressive glomerulonephritis (28 
patients; 280 Tpes)5.
most neurologic disorders that are treated with 
Tpe are associated with presumed aberrant humoral 
immune responses, including mg, guillain-Barré 
syndrome, and CiDp7. The efficacy of Tpe in these 
neurologic disorders has been demonstrated in ran-
domized controlled clinical trials, and the level of rec-
ommendation is high (Tables 2 and 3).
Table 3. Grading recommendations









strong recommendation, can 







RCTs with important 
imitations or exceptionally
strong evidence from obser-
vational studies
strong recommendation, can 










strong recommendation but 
may change when higher qual-
ity evidence becomes available
grade 2A
Weak recommenda-






Weak recommendation, best 
action may differ depending






RCTs with important 
limitations or exceptionally
strong evidence from obser-
vational studies
Weak recommendation, best 
action may differ depending





low-quality or very 
low-quality evidence
observational studies or case
series
very weak recommendations;
other alternatives may be 
equally reasonable
RCT = randomized controlled trial
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This article will review only those situations in 
which a rapid decision whether to use Tpe or not in 
seriously ill neurologic patients is necessary.
Technical Aspects of Therapeutic Plasma 
Exchange
Therapeutic plasma exchange is an extracorporeal 
blood purification technique, designed for the removal 
of large-molecular-weight substances from the plas-
ma. A plasma filter is used to separate plasma from all 
other cellular elements using a semipermeable mem-
brane. plasma filter membrane pores are up to 0.2 µm 
in diameter (approximately 30 times the diameter of 
the pores in conventional high-flux hemofilter mem-
branes), allowing for the removal of substances of a 
molecular weight up to 3x106 Da, which includes im-
munoglobulins, immune complexes, complement fac-
tors, lipoproteins, and endotoxin. As Tpe removes all 
circulating substances in the plasma, care should be 
taken to avoid disturbances with clotting factors, cal-
cium and magnesium levels, and any other substances 
that may be depleted as a result of the procedure. sys-
temic heparinization is used for anticoagulation. The 
fluid volume removed by Tpe must be replaced to 
prevent marked volume depletion. in most pathologic 
conditions in which plasma exchange is used, 1 to 1.5 
plasma volumes (pv) are exchanged per procedure per 
day. There is no consensus on the ideal replacement 
solution for plasma discarded during Tpe. except for 
distinct diseases like TTp or hemolytic uremic syn-
drome (hus) in which substitution is clearly done by 
fresh frozen plasma (FFp), colloid replacement can be 
achieved with the use of FFp, albumin, albumin and 
saline, or albumin and plasma expander solutions8. 
Routine treatment duration of 3 to 5 days may be pro-
longed, depending on the diagnosis and the individual 
patient’s condition. 
Complications associated with Tpe might be re-
lated to blood access, replacement fluids, the proce-
dure itself, or to the use of anticoagulants. Awareness 
of the possible severe complications is one of the major 
barriers for some physicians when considering Tpe 
for their patients. interestingly, although thousands of 
procedures are carried out each year, there are only a 
few reports on complications of Tpe9.
Medical and Scientific Basis for Therapeutic Use 
of Plasma Exchange
There are several mechanisms by which Tpe ex-
erts its beneficial effects. The removal of circulating au-
toantibodies, immune complexes, cytokines, and other 
inflammatory mediators is thought to be the principal 
mechanism of action. Antibodies against self have 
been identified in various neurologic disorders, includ-
ing antibodies against nicotinic acetylcholine receptor 
in mg, antibodies against p/Q-type voltage-gated 
calcium channels in lambert-eaton syndrome, and 
antimyelin oligodendrocyte glycoprotein antibodies in 
multiple sclerosis (ms). Cytokines, including chemok-
ines and complement, are other potentially injurious 
molecules that may be removed by plasmapheresis. 
several other effects of Tpe on immune function have 
been proposed, including immunomodulatory actions 
such as alterations in idiotypic/anti-idiotypic antibody 
balance, a shift in the antibody-to-antigen ratio to more 
soluble forms of immune complexes, and stimulation of 
lymphocyte clones to enhance cytotoxic therapy10. The 
infusion of normal plasma may also replace a deficient 
plasma component, perhaps the principal mechanism 
of action of Tpe in TTp. 
Clinical benefit from Tpe is primarily observed 
in diseases with a self-limited course, whereas a long-
term effect in chronic disorders is less frequently 
achieved. in antibody-mediated diseases, this could 
be due to the removal of an insufficient number of 
pathogenic autoantibodies and their continued syn-
thesis with repeated antigenic stimulation. The intra-
vascular and extravascular distribution of pathogens 
that are desired to be removed by Tpe has to be con-
sidered. most large molecular weight substances have 
considerable concentrations in the extravascular space, 
and after removal of the substance from intravascu-
lar space, there may be rapid substance redistribu-
tion from extravascular into the intravascular space. 
it usually requires repeated treatments with Tpe. 
Complete removal of pathogenic antibodies is impos-
sible to achieve. Because of slow equilibration of large 
macromolecules between the vascular space and the 
interstitium, the rate of removal can be expressed as 
first-order kinetics. The exchange of a single volume 
of plasma will lower the level of a specific macromol-
ecule by 50% to 60%, and an increase to 1.4 pv will 
lower plasma levels by 75%11.
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Therapeutic Plasma Exchange in Neuroimmune 
Disorders 
Acute inflammatory demyelinating 
polyradiculoneuropathy (AIDP; Guillain-Barré 
syndrome)
Acute inflammatory demyelinating polyradicu-
loneuropathy (AiDp; guillain-Barré syndrome) has 
emerged in the past quarter century as the most fre-
quently occurring clinical paralytic disorder. Annual 
incidence approaches 2 cases per 100,000 persons, up 
to 23% may require assisted ventilation, and up to 1 in 
20 patients may die from complications of the disease. 
About 75% of patients suffer persistent minor neuro-
logic deficits, 5% to 15% are disabled by the residua 
of their disease and up to 10% relapse. mortality is 
estimated at 5%. guillain-Barré syndrome is charac-
terized by generalized weakness and distal paresthe-
sias progressing over several days. A typical diagnostic 
feature is an increased concentration of protein in the 
absence of pleocytosis (albumino-cytologic dissocia-
tion) in the cerebrospinal fluid (CsF). A typical case 
of guillain-Barré syndrome presents initially with 
paresthesias of the toes or fingertips, but within days, 
leg weakness sufficient to interfere with walking or 
stair climbing develops. Weakness of the arm, facial, 
and oropharyngeal muscles ensues as the paresthesias 
extend proximally. symmetric limb weakness and ab-
sent deep tendon reflexes are common findings. sen-
sory loss is relatively mild despite the paresthesias. 
Autonomic dysfunction may cause variability in heart 
rate and blood pressure. spontaneous recovery may 
occur usually after three weeks of illness12. Clinical 
variants include the miller-Fisher variant character-
ized by ophthalmoplegia, ataxia, and areflexia with-
out weakness. 
Aberrant humoral and cellular immune response 
systems are involved in the pathogenesis of guil-
lain-Barré syndrome. molecular mimicry, in which 
epitopes incidentally shared by microbial antigens and 
nerve structures elicit an autoreactive T-cell or B-cell 
response in the wake of an infective illness, may trig-
ger the autoimmune process. in about 60% of cases, 
guillain-Barré syndrome follows closely an infec-
tion, most frequently caused by the microbiological 
agent Campylobacter jejuni. Activated T cells migrate 
across the blood-nerve barrier and are reactivated in 
situ when their autoantigen is appropriately displayed 
by macrophages along with major histocompatibility 
complex ii products and co-stimulatory molecules. 
Autoantibodies crossing the blood-nerve barrier en 
passant with T cells or accessing target structures di-
rectly at the most proximal or distal parts of the nerve 
contribute to the inflammatory process by antibody-
dependent cytotoxicity and activation of complement. 
A large variety of antibodies against different glyco-
lipids, including gm1, gD1a, and gQ1b, among 
others, have been described7,12.
severely affected patients with guillain-Barré 
syndrome may require intensive care, mechanical ven-
tilation (Fig.  1), assistance through the paralysis and 
necessary rehabilitation over several months to a year 
or more. Corticosteroids have not been shown help-
ful when used alone. Tpe was the first therapeutic 
modality to impact the disease favorably and several 
major randomized controlled clinical trials have con-
firmed its efficacy (Table 4). in the first study, 245 
patients were included and received Tpe or conven-
Fig. 1. Patient with acute inflammatory demyelinating 
polyneuropathy (AIDP; Guillain-Barré syndrome) on 
mechanical ventilation at Neurologic Intensive Care Unit, 
Zagreb University Hospital Center, Zagreb, Croatia.
Guillain-Barré syndrome is the most common cause of rap-
idly progressive weakness due to peripheral nerve involve-
ment that evolves rapidly (usually over days) and classi-
cally has been described as ascending from legs to arms and, 
in severe cases, to respiratory and bulbar muscles. Between 
10% and 25% of patients require ventilator assistance ini-
tiated within 18 days (mean of 10 days) after onset.
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tional supportive therapy13. Clinical outcomes, that is, 
time to improve by 1 clinical grade and time to in-
dependent walking, were assessed at 4 weeks and 6 
months. in a study conducted by the French Coop-
erative group on plasma exchange in guillain-Barré 
syndrome14, 220 patients were included, 109 of whom 
underwent Tpe and were compared with 111 patients 
defined as the control group. substantial benefit was 
documented for the primary end point, that is, time to 
recover the ability to ambulate with assistance, and in 
secondary factors such as the reduction in the propor-
tion of patients who needed assisted mechanical ven-
tilation, a shorter time to the onset of motor recov-
ery, and clinical factors such as time to walk with and 
without assistance14. The same group has also reported 
long-term benefit in the Tpe population as recovery 
of full muscle strength after 1 year in 71% of patients 
compared with 52% of subjects in the control group15. 
in 1997, a randomized, controlled, nonblinded trial 
included and randomized to 3 groups according to 
degree of disability 556 patients with guillain-Barré 
syndrome. patients with mild disability underwent ei-
ther 0 or 2 Tpe sessions, those with moderate disabil-
ity underwent 2 or 4 sessions, and those with severe 
disability underwent 4 or 6 sessions. it could be dem-
onstrated that 2 vs. 0 Tpe sessions in patients with 
mild disability and 4 vs. 2 Tpe sessions in patients 
with moderate disability were more beneficial. more 
than 4 treatments did not yield additional benefit in 
patients receiving mechanical ventilation in the group 
with severe disability16. Based on several studies of 
class i evidence, Tpe has been established as effective 
treatment in the management of guillain-Barré syn-
drome (Table 5). plasma exchange is most beneficial 
Table 4. Trials of therapeutic plasma exchange in Guillain-Barré syndrome






Tpe vs. supportive care. 
single blinded 245
improvement at 4 wk, time to improve by 1 
clinical grade, time to independent walking, 






Tpe (4x) with albumin vs. 
Tpe (4x) with FFp vs. no 
Tpe. nonblinded
22
shorter time to recover walking with assistance 
(30 vs. 44 d; P<0.01) in Tpe group; fewer 
patients requiring assisted ventilation, shorter 







Three groups: mild disabil-
ity, 0 vs. 2 Tpe; moderate 
disability, 2 vs. 4 Tpe; se-
vere disability, 4 vs. 6 Tpe. 
nonblinded
556
Two Tpe more effective than 0 for time to onset 
of motor recovery (4 vs. 8 d; P<0.001) in group 
with mild disability. Four Tpe superior to 2 
Tpe for time to walk with assistance (20 vs. 24 
d; P=0.04) in group with moderate disability. no 




Tpe (5x) vs. ivig (0.4 g/
kg per day, 5 d). nonblind-
ed, bias controlled.
150
improvement by 1 point on functional score, 
34% in Tpe group vs. 53% in ivig group 
(P=0.02); time to improvement by 1 grade 41 
vs. 27 d (P=0.05). Both treatments are of equal 







Tpe (5x) vs. ivig (0.4 
g/kg/d, 5 d) vs. Tpe (5x) 
+ ivig (0.4 g/kg/d, 5 d). 
single blinded.
383
no significant difference in major outcome mea-
sure (improvement on disability scale after 4 wk) 
or secondary outcome measures (time to recovery 
of unaided walking and time to discontinuation 
of mechanical ventilation).
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when started within 7 days of disease onset, but is also 
efficacious when started after 30 days17,18. 
Chronic Inflammatory Demyelinating Polyradi-
culoneuropathy (CIDP)
patients with chronic inflammatory demyelinating 
polyradiculoneuropathy (CiDp) have a progressive 
clinical course with worsening symmetric proximal 
and distal weakness. The progressive clinical symp-
toms last for longer than 8 weeks. This disorder may 
be seen in the setting of other underlying diseases, 
including hodgkin’s disease, connective tissue dis-
eases, inflammatory bowel disease, hepatitis, diabetes 
and infection with human immunodeficiency virus 
(hiv). patients with monoclonal gammopathies can 
present similar findings. The diagnosis of CiDp is 
largely made clinically, but CsF may reveal elevated 
protein. nerve biopsies show histologic evidence of 
demyelination with mononuclear infiltrate. evidence 
of demyelination is also present on electrophysiologi-
cal testing7,12. 
The presence of autoantibodies against various pro-
teins and glycolipids of the peripheral nerve in samples 
of serum and CsF from patients with CiDp may pro-
vide a rationale for therapeutic use of Tpe (Table 
6). Treatment usually consists of either corticoster-
oid therapy or intravenous immunoglobulin (ivig) 
or Tpe, followed by long-term immunosuppression 
with cyclosporine, interferon, azathioprine, cyclo-
Table 5. Acute inflammatory demyelinating polyneuropa-
thy (AIDP; Guillain-Barré syndrome)
incidence 1 to 2 per 100,000/year
Category i
Recommendation grade 1A
Type of evidence Type i
procedure Tpe
Replacement fluid Albumin
volume treated 1 to 1.5 pv
Frequency every other day
Duration/discontinuation/number of procedures:
5 to 6 Tpe over 10 to14 days are recommended.
Technical notes: 
The typical Tpe strategy is to exchange 200-250 ml 
of patient plasma per kg body weight over 10 to 14 
days. This will generally require 5 to 6 Tpe procedures 
with 5% albumin replacement. Fresh frozen plasma is 
not routinely used for replacement. since autonomic 
dysfunction may be present, affected patients may be 
more susceptible to volume shifts, blood pressure and 
heart rate changes during extracorporeal treatment. 
Relapses may occur in approximately 10% of patients 
2 to 3 weeks following either treatment with Tpe. 
When relapses occur, additional therapy, usually Tpe, 
can be helpful. in AiDp patients with axonal involve-
ment, Tpe has been reported to be of greater potential 
benefit than ivig.
Table 6. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
incidence 1 to 2 per 100,000/year
Category i
Recommendation grade 1B
Type of evidence Type i
procedure Tpe
Replacement fluid Albumin
volume treated 1 to 1.5 pv
Frequency 2 to 3 pe/week until improvement, then taper as tolerated
Duration/discontinuation/number of procedures:
Tpe provides short-term benefit but rapid deterioration may occur afterwards. This may necessitate maintenance 
treatment, with Tpe and/or other immunomodulating therapies, which should be tailored to the individual pa-
tient. The frequency of maintenance Tpe may range from weekly to monthly as needed to control symptoms.
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phosphamide, or other immunosuppressive therapies5. 
Therapeutic response is measured by improvement or 
stabilization in neurologic symptoms, at which point 
treatment can be tapered or discontinued. Between 
60% and 80% of patients respond to initial therapy, 
but long-term prognosis varies19. 
Myasthenia Gravis (MG)
myasthenia gravis (mg) is an autoimmune syn-
drome caused by the failure of neuromuscular trans-
mission (clinically characterized by fluctuating muscle 
weakness and fatigability), which results from the 
binding of autoantibodies to proteins involved in sig-
naling at the neuromuscular junction. The most com-
mon variant of the disease is mediated by circulating 
autoantibodies against the nicotinic acetylcholine re-
ceptor (AChR). These antibodies can be detected in 
75% to 95% of patients with mg. The mechanisms re-
sponsible for the loss of functional AChR that compro-
mise or abort safe neuromuscular transmission include 
degradation of the AChR, complement-mediated lysis 
of the AChR, and interference with neurotransmitter 
binding. in subgroups of patients negative for AChR 
antibody, other antibodies with different specificities 
can be detected, for example, antibodies against the 
muscle-specific receptor tyrosine kinase20. 
The disease is characterized by weakness and fati-
gability with repetitive physical activity, which usual-
ly improves with rest. Common presentation includes 
ptosis and diplopia with more severe cases having fa-
cial, bulbar, and limb muscle involvement. The disease 
is more prevalent in 20- to 40-year-old women.
myasthenic crisis is characterized by acute respira-
tory failure requiring intubation, prolonged intubation 
following thymectomy, or bulbar weakness causing 
dysphasia and high risk of aspiration. Thymic abnor-
malities, such as hyperplasia or thymoma, are com-
monly associated with mg. otherwise, crisis may be 
precipitated by other illnesses, such as influenza or 
other infections. 
With modern treatment regimens, the mortality 
from mg has greatly decreased from 30% to less than 
5%. The four major treatment approaches include 
cholinesterase inhibitors, thymectomy, immunosup-
pression, and either Tpe or ivig. Cholinesterase 
inhibitors (e.g., pyridostigmine bromide) delay the 
breakdown and increase the availability of acetylcho-
line at the motor end plate and lead to variable im-
provement in strength. Thymectomy leads to clinical 
improvement in many patients under the age of 65, but 
it may take years for the benefits to show. immunosup-
pressive drugs (corticosteroids, cyclosporine, azathio-
prine, and tacrolimus) have a delayed effect and there-
fore play an important role in long-term rather than 
short-term management. plasma exchange might be 
useful in myasthenic crisis and in the preoperative and 
postoperative phases of thymectomy in severe forms 
of mg21,22. it is presumed that elimination of circu-
lating AChR antibodies and other humoral factors 
of pathological significance account for the observed 
beneficial effects of Tpe. Both seropositive and sero-
negative patients respond to Tpe. Clinical effect can 
be apparent within 24 hours, but may take a week. 
The benefits will likely subside after 2 to 4 weeks, if 
immunosuppressive therapies are not initiated to keep 
antibody levels low5,23 (Table 7).
A randomized, controlled, 3-armed trial compared 
Tpe with 2 regimens of ivig in the treatment of acute 
exacerbations in mg. eighty-seven patients were ran-
domized either to undergo 3 Tpe sessions or to receive 
ivig (0.4 g/kg per day) for 3 or 5 consecutive days. As 
a primary outcome measure, the change in myasthenic 
muscular score between randomization and day 15 was 
chosen. secondary end points included, among oth-
ers, the decrease of anti-AChR antibody titers. Clini-
cal improvement was observed in all patients, but no 
statistically significant difference in the primary end 
point or in the effect on anti-AChR antibodies be-
tween the 2 groups (Tpe vs. ivig) was documented. 
Adverse effects were less frequent in the ivig group24. 
A retrospective multicenter chart review of 54 myas-
thenic episodes compared the two treatment modali-
ties for myasthenic crisis. patients received either 5 or 
6 Tpe of 25-45 ml/kg on alternate days or 0.4g /kg/
day 3 to 5 days of ivig. Tpe resulted in significantly 
more improvement than ivig in ventilatory status at 
2 weeks and overall outcome at 1 month25.
Paraproteinemic Polyneuropathies (PP)
A number of common disorders of the peripheral 
nervous system, termed paraproteinemic polyneurop-
athies (pp), are closely connected with the presence of 
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excessive amounts of an abnormal immunoglobulin in 
the blood. These immunoglobulins can be detected by 
immunoelectrophoresis or the more sensitive immuno-
fixation test. An estimated 10% of idiopathic polyneu-
ropathies are of this type. The anomalous blood pro-
teins are usually monoclonal (termed m protein or m 
spike), the product of a single clone of plasma cells, and 
some of them have the properties of antibodies directed 
at the components of the myelin or axolemma. others 
have an uncertain pathophysiological role intermediate 
between that of proteins associated with neuropathies 
and that of proteins associated with lymphoprolifera-
tive disorders. The nerves may also be damaged by de-
position of the amyloid byproduct of the circulating 
paraprotein. These neuropathies are typically associ-
ated with a monoclonal gammopathy of non-neoplastic 
origin, multiple myeloma, Waldenström’s macroglobu-
linemia, osteosclerotic myeloma, primary amyloidosis, 
cryoglobulinemia, non-hodgkin’s lymphoma, Castle-
man’s disease and related lymphatic diseases, and 
chronic leukemias26. The diagnosis can be established 
based on electrophysiological studies and the presence 
of monoclonal proteins. pp are most commonly seen 
in the setting of monoclonal gammopathy of undeter-
mined significance (mgus), especially igm-mgus. 
in 50% of igm-mgus, the specificity of igm is my-
elin glycoprotein (mAg). This specificity has also been 
seen in Wm, Cll, igg- and igA-mgus. symptoms 
tend to progress more rapidly in patients with igm 
compared to igA- or igg-mgus5.
The principal confirmation that antinerve antibod-
ies that are a component of a paraprotein are linked to 
neural damage has been derived from the detection 
by direct immunofluorescent staining of endoneur-
ial deposits of immunoglobulin and complement in 
nerve and the induction of demyelinating neuropathy 
in animals by immunization with the aforementioned 
antigens, by transfer of serum from patients with the 
disease, and by intraneural injection. in all these in-
stances, the case for pathogenic activity of igm anti-
bodies directed against myelin glycoprotein (mAg), 
gangliosides, and other glycosphingolipids is better 
established than that for other antigens and for igg 
and igA antibodies.
in a randomized, controlled, double-blind trial, 
Dyck et al.27 studied the effectiveness of Tpe in the 
treatment of polyneuropathy associated with mgus. 
Thirty-nine patients were randomly assigned to receive 
Table 7. Myasthenia gravis (MG)
incidence 1 per 100,000/year
Category
















volume treated 1 to 1.5 pv
Frequency Daily or every other day
Duration/discontinuation/number of procedures:
A typical induction regimen consists of processing 225 ml/kg of plasma over a period of up to 2 weeks but smaller 
volume processing can be beneficial. The number and frequency of procedures depend upon the clinical scenario. 
some patients may require long-term maintenance Tpe.
146 Acta Clin Croat,  Vol. 51,   No. 1,  2012
p. Kes et al. Therapeutic plasma exchange in the neurologic intensive care setting 
either Tpe twice weekly for 3 weeks or sham treat-
ment. Based on its effects on the 2 primary outcome 
measures, that is, the neuropathy disability score and 
the summed compound muscle action potentials of 
motor nerves, a treatment benefit was suggested for 
Tpe, whereas in secondary end points, that is, nerve 
conduction velocity and sensory nerve action potentials, 
no statistically significant differences were found. The 
study demonstrated, furthermore, that patients with 
igg or igA gammopathy benefit more than those with 
igm gammopathy. hence, Tpe can be recommended 
in at least this subgroup of patients (Table 8).
Acute Disseminated Encephalomyelitis (ADEM)
Acute disseminated encephalomyelitis (ADem) 
is a neurologic disorder characterized by inflamma-
tion of the brain and spinal cord caused by damage to 
the myelin sheath. The myelin sheath is the fatty cov-
ering, which acts as an insulator, on nerve fibers in the 
brain. ADem may occur in association with a viral 
or bacterial infection, as a complication of inoculation 
or vaccination, or without a preceding cause. The on-
set of the disorder is sudden. symptoms, which vary 
among individuals, may include headache, delirium, 
lethargy, coma, seizures, stiff neck, fever, ataxia, op-
tic neuritis, transverse myelitis, vomiting, and weight 
loss. other symptoms may include monoparesis (pa-
ralysis of a single limb) or hemiplegia (paralysis on one 
side of the body). The disorder occurs in children more 
often than in adults. The mortality rate is around 5%, 
with complete recovery in 50% to 75% of cases28.
magnetic resonance imaging (mRi) is the diag-
nostic imaging modality of choice for demyelinat-
ing lesions of ADem. Characteristic lesions seen on 
mRi appear as patchy areas of increased signal inten-
sity with typical involvement of deep cerebral hemi-
spheric and subcortical white matter, as well as lesions 
in the basal ganglia, gray-white junction, brain stem, 
cerebellum and spinal cord. 
Table 8. Paraproteinemic polyneuropathies (PP)
incidence monoclonal gammopathy of undetermined significance: up to 3% of general population over 50 years old
Category
demyelinating polyneuropathy with igg/igA- 




demyelinating polyneuropathy with igg/igA- 
polyneuropathy with igm- 
grade 1B
grade 1C
Type of evidence Type i
procedure Tpe
Replacement fluid Albumin; plasma
volume treated 1 to 1.5 pv
Frequency every other day
Duration/discontinuation/number of procedures:
The typical course is 5 to 6 treatments over the course of 10 to 14 days. long term Tpe or slow tapering off Tpe 
can be considered. The patient may continue to improve over weeks following cessation of Tpe. if the level of 
paraprotein is correlative to the polyneuropathy, then it can be monitored to evaluate the frequency of treatment. 
however, the titer of the paraprotein may not correlate with the clinical disease state.
Technical notes: 
patients with demyelinating pp may be treated at any time in their course (including patients referred up to 4 years 
after the onset of symptoms).
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Therapeutic aim is to abbreviate the central ner-
vous system (Cns) inflammatory reaction as quickly 
as possible, and to speed up clinical recovery. Cor-
ticosteroids are considered effective because of their 
anti-inflammatory and immunomodulatory effects 
with additional beneficial effect on cerebral edema. 
Corticosteroids hasten recovery and result in clinical 
improvement in up to 60% of patients. Tpe should 
be considered for patients with severe ADem, who 
respond poorly to steroid treatment or in whom it is 
contraindicated. Tpe is used and has a clearly defined 
role in other neurologic conditions that are presumed 
to be immune mediated. Tpe works by removing the 
presumed offending autoantibodies as well as through 
immunomodulation (Table 9). in the acute phase of 
ADem, cytokines such as tumor necrosis factor, 
soluble tumor necrosis factor receptor 1, il-6 and il-
10 are elevated. Antibodies to gangliosides, such as 
gm1 and CD1a, and myelin basic protein-reactive T-
helper 2 cells, may be present, which can be removed 
by Tpe5.
Chronic Focal Encephalitis (Rasmussen’s 
Encephalitis)
Rasmussen’s encephalitis, a form of chronic fo-
cal encephalitis, is a rare inflammatory brain dis-
ease characterized by severe intractable epilepsy and 
unilateral progressive motor defect associated with 
contralateral hemispheric atrophy. The disorder usu-
ally affects children, although occasional reports of 
adult-onset Rasmussen’s syndrome have been report-
ed. Cumulative evidence suggests that Rasmussen’s 
encephalitis has an autoimmune etiology. pathologic 
hallmarks are inflammation and gliosis in the affected 
cerebral hemisphere. Focal disruption of the blood-
brain barrier, perhaps caused by focal seizures, may 
allow the access of pathologic humoral factors to brain 
tissue. Antibodies directed against the glutamate re-
ceptor gluR3 have been detected in serum samples 
of patients with Rasmussen’s encephalitis. A major 
pathogenic role of anti-gluR3 antibodies has been 
challenged because they have also been identified in 
patients with focal epilepsy and (in lower frequency) 
in other neurologic diseases, and their contribution 
remains unresolved. Cytotoxic CD8 T cells have been 
identified in the brains of affected individuals with 
Rasmussen’s encephalitis, and it has been suggested 
that their direct assault on neurons underlies the dis-
ease pathogenesis10. 
Clinical diagnosis in the early stages is often dif-
ficult as the patient may present with generalized sei-
zures, but the later stage is easier to recognize when 
the patients present with epilepsia partialis and hemi-
Table 9. Acute disseminated encephalomyelitis (ADEM)
incidence 0.8 per 100,000/year
Category ii
Recommendation grade 2C
Type of evidence Type iii
procedure Tpe
Replacement fluid Albumin
volume treated 1 to 1.5 pv
Frequency Daily or every other day
Duration/discontinuation/number of procedures:
There is no clear standard based upon which to make recommendations as to the optimum use of Tpe in ADem. 
in the largest case study, Tpe achieved moderate and marked sustained improvement in 50% of patients. Factors 
associated with improvement include male sex, preserved reflexes and early initiation of treatment. in most pub-
lished literature, response was noticeable within days, usually after 2 to 3 exchanges. if improvement is not observed 
early in the course of treatment, then response is unlikely to occur. Tpe therapy consists of 3 to 6 treatments.
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paresis. A combination of clinical criterion, imaging 
studies, electroencephalography and antibody titers 
will identify most cases.
Anticonvulsants are necessary, but not always ef-
fective. Based on recent pathogenic concepts, differ-
ent medical treatments including ivig, iv. methyl-
prednisolone and oral prednisone, intraventricular 
interferon-α given via omaya reservoir, iv. rituximab 
and tacrolimus have been investigated for control 
of epileptic and neurologic aspects of Rasmussen’s 
syndrome. surgical hemispheric disconnection that 
appears the most effective treatment in children to 
improve seizure control is not indicated in adults for 
evident functional reasons. significant early improve-
ment has been shown with Tpe in children with 
Rasmussen’s encephalitis. This treatment was based 
on the demonstration of serum immunoreactivity to 
the gluR3 in such patients5,29. Despite the paucity of 
clinical reports, investigators in the field recommend 
a concerted trial of immunotherapy, including Tpe 
(Table 10), to control seizures, mitigate functional 
decline, and delay the need for hemispherectomy in 
patients with Rasmussen’s encephalitis.
Lambert-Eaton Myasthenic Syndrome (LEMS)
lambert-eaton myasthenic syndrome (lems) 
is an immune-mediated, presynaptic neuromuscular 
junction disorder mediated by antibodies against neu-
ronal p/Q-type voltage-gated calcium channels. The 
disease is characterized by muscle weakness and au-
tonomic dysfunction. in more than 90% of patients, 
muscle weakness starts proximally in the legs, and 
thereafter may spread to other skeletal muscles in a 
caudo-cranial order. in some patients, this might lead 
to the need for artificial respiration. ptosis and diplo-
pia can be present, but tend to be milder than in auto-
immune mg. mild to moderate autonomic dysfunc-
tion in lems is characterized by the presence of dry 
mouth, dryness of the eyes, blurred vision, impotence 
and constipation, and is mostly mild to moderate. 
in about 60% of patients, lems is associated with 
small cell lung carcinoma, but it can also occur outside 
the context of neoplasia. in rare cases, patients with 
lems and small cell lung cancer develop paraneo-
plastic cerebellar degeneration30. 
initial management should be directed at treat-
ment of the underlying malignancy because weakness 




Type of evidence Type ii-3
procedure Tpe
Replacement fluid Albumin/saline
volume treated 1.5 to 2 pv
Frequency Tpe: 3-6 Tpe over 6-12 days; repeat monthly; alternative schedule: Tpe weekly
Duration/discontinuation/number of procedures:
After an initial course of treatment, subsequent courses of Tpe (with or without ivig) may be performed at in-
tervals of 1 to 2 weeks or up to 2 to 3 months as empirically needed to maintain clinical stability and avoid or delay 
hemispherectomy. immunosuppressive medications may increase the interval between the courses. surgical treat-
ment is offered for the management of patients who exhibit functional or cognitive decline or intractable seizure 
activity despite intensive immunomodulatory therapy.
Technical notes: 
neuropsychological assessment may be helpful in evaluating patients with slowly progressive disease to determine 
whether Tpe is effective in postponing surgical therapy.
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frequently improves with effective cancer therapy. 
Apart from underlying malignancy, the management 
of lems is directed toward support immunosuppres-
sion to control production of the offending antibodies 
and support of acetylcholine-mediated neurotransmis-
sion to improve neurologic function. Cholinesterase 
inhibitors such as pyridostigmine alone, or combined 
with guanidine hydrochloride, that act to enhance the 
release of acetylcholine from the presynaptic nerve 
terminal, may produce some improvement in lems. 
3,4-Diaminopyridine is effective therapy in lems 
and may be combined with pyridostigmine5,23. in 
patients with significant weakness, prednisone, aza-
thioprine, cyclosporine or cyclophosphamide can be 
used. The identification of lems as an autoantibody-
mediated syndrome has led to several attempts to use 
Tpe and ivig in its treatment (Table 11). Tpe may 
be a useful adjunct to the management of patients with 
lems whose neurologic deficit is severe or rapidly 
developing, or patients who are too uncomfortable to 
wait for immunosuppressive or aminopyridine drugs 
to take effect, or who cannot tolerate treatment with 
ivig. The effects are short-lived unless immunosup-
pressant drugs are used, and additional courses are of-
ten needed to maintain benefit. improvement may last 
for ever longer periods after each treatment.
Multiple Sclerosis (MS)
multiple sclerosis (ms) is a multifocal inflamma-
tory disease of the Cns, characterized by chronic in-
flammation, demyelination, axonal damage, and sub-
sequent gliosis. Current concepts of its pathogenesis 
assume that in genetically susceptible individuals, po-
tentially self-reactive T cells are activated in the im-
mune system, home onto the Cns, and may initiate 
tissue damage via release of inflammatory cytokines, 
stimulation of B cells and macrophages, and activation 
of the complement system. Antibodies against myelin 
basic protein and myelin oligodendrocyte glycoprotein 
have been detected in subgroups of patients with ms. 
These antibodies may mediate injury by complement 
fixation or linking with innate immune effector cells 
such as macrophages31. 
Clinical symptoms include sensory disturbances, 
unilateral optic neuritis, diplopia, limb weakness, gait 




Type of evidence Type ii-3
procedure Tpe
Replacement fluid Albumin
volume treated 1 to 1.5 pv
Frequency Daily or every other day
Duration/discontinuation/number of procedures:
Treatment should continue until a clear clinical and emg response is obtained or at least until a 2- to 3-week 
course of Tpe has been completed. Repeated courses may be applied in case of neurologic relapse, but the effect 
can be expected to last for only 2 to 4 weeks in the absence of immunosuppressive drug therapy.
Technical notes: 
The reported Tpe regimens vary from 5-15 daily Tpe over 5-19 days to 8-10 Tpe carried out at 5-7 day inter-
vals. most reports indicate an exchange volume of 1.25 plasma volumes.
Of note: improvement may not be seen for 2 weeks or more after initiation of plasma exchange therapy. This may 
be due to the slower turnover of the presynaptic voltage gated calcium channel compared to the postsynaptic ace-
tylcholine receptor.
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ataxia, neurogenic bladder and bowel symptoms. mRi 
shows multiple lesions of different ages involving the 
white matter of the cerebrum, brain stem, cerebellum, 
and spinal cord. A more severe clinical course can be 
predicted by frequent relapses in the first 2 years, pri-
mary progressive form, male sex, and early permanent 
symptoms10.
patients with ms may have benefit from Tpe by 
removing an autoantibody, such as anti-myelin anti-
body, or modulating immune response. in acute, se-
vere attacks of ms in patients who fail initial treat-
ment with high-dose steroids, Tpe may be beneficial 
(Table 12). however, no major therapeutic effect of 
Tpe can be expected once antibodies have been de-
posited in situ in Cns lesions. Treatment in relapsing-
remitting ms includes azathioprine, ivig, interferon 
β-1a, glatiramer acetate, mitoxantrone hydrochloride, 
natalizumab, and cyclophosphamide depending on 
the disease severity. Tpe has not been specifically 
studied in relapsing-remitting ms. An appropriate 
treatment for primary progressive ms does not exist. 
multiple randomized controlled trials demonstrate 
small to no benefit of Tpe in conjunction with other 
immunosuppressive drugs in patients with chronic 
progressive ms5,32.
Neuromyelitis Optica (NMO; Devic’s Disease)
neuromyelitis optica (nmo; Devic’s syndrome) 
is a severe idiopathic inflammatory demyelinating 
disease that selectively affects optic nerves and spinal 
cord, typically spares the brain, and generally follows 
a relapsing course. over 70% of nmo cases are as-
sociated with nmo-igg which binds to aquaporin-4 
(a water channel) on astrocyte foot processes at the 
blood-brain barrier. histopathology of nmo includes 
deposition of igg and complement in the perivascular 
space with a granulocyte and eosinophil infiltrate, and 
hyalinization of vascular walls5,33. Within 5 years, 50% 
of patients lose functional vision on at least one eye or 
are unable to walk independently. early and accurate 
diagnosis is important because nmo carries a poorer 
prognosis than ms and generally accepted treatment 
approaches differ (34). Distinction from ms is by fe-
male predominance (1:4-5 male:female), longitudinal 
spinal cord lesions (3 or more vertebral segments), and 
CsF with negative oligoclonal igg bands and leuko-
cytosis34. in addition, brain mRi is not typical for ms. 
nmo is associated with other autoimmune diseases, 
such as systemic lupus erythematosus, sjögren’s dis-
ease, mg, viral infections and vaccinations. Disease 
course may be monophasic or relapsing. monophasic 
course is associated with younger age at disease onset 
and equal male:female predominance. monophasic 
Table 12. Multiple sclerosis (MS)
incidence 5 to 30 per 100,000/year
Category
– acute Cns inflammatory demyelinating disease 
unresponsive to steroids ii
Recommendation grade 1B
Type of evidence Type i
procedure Tpe
Replacement fluid Albumin
volume treated 1 to 1.5 pv
Frequency Acute 5 to 7 (or even 14 days)
Duration/discontinuation/number of procedures:
in acute ms unresponsive to steroids, 5 to 7 Tpe procedures have a response rate of approxi-
mately 50%. 
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course has a 90% 5-year survival rate. Approximately 
80% of patients with nmo have relapsing course, 
which has a poor prognosis: 50% of patients become 
legally blind or wheelchair bound and 30% die from 
respiratory failure within 5 years (5). nmo worsens 
by incomplete recovery with each acute attack.
Acute attacks are managed by high-dose intrave-
nous steroids and, if it fails to resolve symptoms Tpe 
is added. Tpe removes the pathologic antibody, im-
mune complexes, and inflammatory mediators. Re-
lapses are commonly resistant to steroids, and Tpe 
can be helpful in recovery from acute attack but does 
not prevent further relapses (Table 13). prophylaxis 
to prevent further acute attacks includes immunosup-
pressive medications and immunomodulation, such as 
rituximab (anti-CD20), methotrexate, interferon, aza-
thioprine, cyclophosphamide, prednisone, ivig, mi-
toxantrone, interferon, and mycophenolate mofetil35. 
patients at high risk of relapse include those who are 
seropositive for nmo-igg.
Conclusions
The role of Tpe in the neurologic intensive care 
unit has changed over past 35 years. it is known that 
autoantibodies and immune complexes play a crucial 
role in many kinds of neurologic autoimmune disease. 
it has been recognized that removing these (autoan-
tibodies and immune complexes) and some other 




Type of evidence Type ii-3
procedure Tpe
Replacement fluid Albumin
volume treated 1 to 1.5 pv
Frequency Daily or every other day
Duration/discontinuation/number of procedures:
The majority of studies performed 5 Tpe on average (range 2 to 20 procedures). The patients who received Tpe 
had lower residual disability scores (results from a retrospective cohort study). in case series, 50% to 70% of patients 
showed improvement after Tpe, but all patients had received steroids.
pathogenic substances (inflammatory mediators, 
complement components, and cytokines) from patient 
plasma is an efficient means of treatment. in various 
neurologic disorders, randomized controlled studies 
have demonstrated the efficacy of Tpe, e.g., in acute 
inflammatory demyelinating polyneuropathy (AiDp; 
guillain-Barré syndrome), chronic inflammatory 
demyelinating polyradiculoneuropathy (CiDp), my-
asthenia gravis (mg), and paraproteinemic polyneu-
ropathies (pp). For these disorders, Tpe is accepted as 
first-line therapy, either as a primary standalone treat-
ment or in conjunction with other modes of treatment. 
Although widely used, the potential benefit of Tpe in 
the treatment of acute disseminated encephalomyeli-
tis (ADem), chronic focal encephalitis (Rasmussen’s 
encephalitis), lambert-eaton myasthenic syndrome 
(lems), multiple sclerosis (ms), and neuromyelitis 
optica (nmo; Devic’s disease) is less clear. For these 
disorders, Tpe is accepted as second-line therapy, ei-
ther as a standalone treatment or in conjunction with 
other modes of treatment.
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TeRApiJsKA iZmJenA plAZme u neuRološKoJ JeDiniCi inTenZivnog liJečenJA 
P. Kes, V. Bašić-Kes, N. Bašić-Jukić i V. Demarin 
Terapijska izmjena plazme (Tip) je dobro poznata terapijska metoda koju se rabi u liječenju brojnih imuno posredo-
vanih neuroloških bolesti. povoljni učinci Tip ostvaruju se uklanjanjem plazmatskih uzročnika bolesti odnosno auto-
antitjela, imunih kompleksa, posrednika upale, sastavnica komplementa i citokina koji imaju ključnu ulogu u nastanku 
neuroloških autoimunih bolesti. Randomizirana, kontrolirana istraživanja dokazala su učinkovitost Tip u liječenju slije-
dećih neuroloških bolesti: akutna upalna demijelinizirajuća polineuropatija (AuDp; guillain-Barréov sindrom), kronična 
upalna demijelinizirajuća poliradikulopatija (KuDp), mijastenija gravis (mg) i paraproteinemijske polineuropatije (pp). 
u tim je bolestima Tip prihvaćena kao prvi izbor liječenja, kao jedina metoda ili u kombinaciji s drugim terapijskim me-
todama. učinkovitost liječenja pomoću Tip manje je uvjerljiva u neurološkim bolestima kao što su akutni diseminirani 
encefalomijelitis (ADem), kronični fokalni encefalitis (Rasmussenov encefalitis), lambert-eatonov mijastenični sindrom 
(lems), multipla skleroza (ms) i optički neuromijelitis (on; Deviceva bolest). u tim bolestima Tip je prihvaćena kao 
drugi izbor liječenja, i to kao jedina metoda ili u kombinaciji s drugim vrstama liječenja. 
Ključne riječi: Akutni diseminirani encefalomijelitis; Akutna upalna demijelinizirajuća polineuropatija; Kronični fokalni 
encefalitis; Kronična upalna demijelinizirajuća poliradikulopatija; Lambert-Eatonov mijastenični sindrom; Multipla skleroza; 
Mijastenija gravis; Optički neuromijelitis; Paraproteinemijske polineuropatije; Terapijska izmjena plazme
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